Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron and vitamins, pain management, preterm labor management, antiemetic, PPI; vitamin K1, zinc supplement, antiallergic, vitamin D3, digestive enzyme, promolact, antipyretic, and childcare, as well as products for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations to approximately 25 countries, including the Philippines, Myanmar, Sri Lanka, Vietnam, Cambodia, D.R. Congo, Ghana, Nigeria, Mozambique, Zambia, Kenya, lvory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, Ecuador, the United Kingdom, the United States, Moldova, and Jamaica. Mercury Laboratories Limited was founded in 1962 and is headquartered in Vadodara, India.
Metrics to compare | MRCU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRCUPeersSector | |
---|---|---|---|---|
P/E Ratio | 33.1x | 31.4x | −0.5x | |
PEG Ratio | −0.75 | 0.14 | 0.00 | |
Price/Book | 1.9x | 3.7x | 2.6x | |
Price / LTM Sales | 1.4x | 4.1x | 3.2x | |
Upside (Analyst Target) | - | 11.3% | 45.7% | |
Fair Value Upside | Unlock | −5.0% | 8.6% | Unlock |